We are looking for an experienced and enthusiastic ADME/DMPK scientist with a proven track record in the field of small molecule in vitro ADME to join the department of Translational DMPK. The department is a key component of the Research organization where we interact closely with other functions such as medicinal and computational chemistry, pharmacology and toxicology to discover and optimize new molecules for CNS diseases. The department is thus fully integrated in the drug discovery process supporting optimization of the DMPK properties of both small and large molecules from early target validation studies through Lead Optimization to selection, profiling and risk assessment of clinical drug candidates.
Main responsibilities will include provision of DMPK input and guidance to drug discovery programs as DMPK representative sitting within multi-disciplinary drug discovery project teams. The role of the DMPK representative is to interpret and guide research design teams on key aspects of in vitro ADME and pharmacokinetic properties including drug metabolism, metabolite structure elucidation and drug-drug interaction assessment. Further to this, you will be involved in adapting and executing the department strategy within the area of biotransformation/metabolism to meet the evolving needs of the discovery projects. The department is continuously looking to refine and expand our assay platform and capabilities to increase the mechanistic ADME understanding and translation to humans of small molecule drug leads. As a senior/principal scientist you will specifically be involved in maximizing our capabilities within the areas of CYP/non-CYP metabolism, metabolite structure elucidation, metabolic soft-spot identification, reactive metabolite identification/risk assessment and drug-drug interactions.
Lundbeck is a global pharmaceutical company with approximately 5,000 employees specialized in psychiatric and neurological disorders. At Lundbeck we are highly committed to improving the quality of life of people living with brain disease. Translational DMPK is part of the Division of Molecular Discovery and Innovation within Lundbeck Research. The department consists of a mix of 16 skilled scientists, technicians and PhD students and is based at Lundbeck’s headquarters in Valby, Copenhagen. Research studies and assays are conducted inhouse in modern DMPK and bioanalysis laboratories as well as at specialized CRO’s around the world. This is a great opportunity to join a research team dedicated to optimizing the DMPK properties and building the understanding of translation to humans for new molecules targeting CNS diseases.
Our preferred candidate is a scientist with comprehensive experience in mechanistic ADME in the field of small molecule biotransformation and metabolism. Further, we are looking for a candidate with the following profile:
Applications should be received no later than June 25th, 2020 by using the link below and should include a cover letter with curriculum vitae. Names and contact details for one or two referees are welcomed. For further information please contact Christoffer Bundgaard, Senior Manager and Head of Translational DMPK on CHBG@lundbeck.com or +45 30 83 57 85.